INO Bulls Loading Above Key SupportInovio Pharmaceuticals, Inc.BATS:INOTaxpayerTradesAfter a powerful move off the summer lows, INO continues to consolidate above a critical support area while maintaining a bullish pennant structure on the daily chart. Rather than giving back the entire rally, price has spent the last several weeks building a base above the key breakout zone near $1.00-$1.05. This type of consolidation often serves as a reset phase before the next directional move, and bulls remain in control as long as support continues to hold. The pattern remains attractive from a risk-to-reward perspective, with the active bullish pennant projecting a potential move toward $2.48 while providing a clearly defined invalidation level below support. Why I'm Watching INO ✅ Bullish pennant remains active ✅ Price holding above key support ✅ Higher-low structure intact ✅ Strong risk/reward profile ✅ Pattern target near $2.48 Major Catalysts 📰 INOVIO Pharmaceuticals' lead candidate, INO-3107, is currently under FDA review with a PDUFA target date of October 30, 2026. This is arguably the most important catalyst on the horizon and could be a significant driver of volatility. 📰 ApolloBio, INOVIO's partner in China, recently reported positive Phase 3 topline results for VGX-3100 in cervical dysplasia and intends to pursue regulatory submission in China, potentially creating future milestone and royalty opportunities. 📰 INOVIO Pharmaceuticals also maintains an active pipeline across HPV-related diseases, oncology, and infectious diseases, providing additional opportunities for future clinical and regulatory updates. What Bulls Need The next technical hurdle is a breakout above the recent highs around $1.35-$1.40. A decisive move through that level could increase momentum and improve the probability of a run toward higher resistance zones. Key Levels Support: $1.00 - $1.05 Resistance: $1.35 - $1.40 Major Resistance: $1.75 - $2.00 Bullish Target: $2.48 As long as INO continues to hold above support, the bullish setup remains intact. With a major FDA catalyst approaching and the chart still respecting its higher-low structure, this is a name worth keeping on the watchlist. Not financial advice. Always do your own research and manage risk accordingly.